IRON
What one share of Disc Medicine holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. We have assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
Disc Medicine’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$6.56 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$5.27 |
| Cash and investments | $18.72 |
| Debt | $1.55 |
| Book value | $16.80 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$2.70 | $0.00 | −$2.17 | — | −$1.85 |
| 2021 | — | −$40.95 | $0.08 | −$31.42 | — | −$70.60 |
| 2022 | — | −$45.05 | $0.15 | −$40.79 | — | — |
| 2023 | — | −$3.42 | $0.00 | −$3.30 | — | $14.17 |
| 2024 | — | −$3.96 | $0.02 | −$3.42 | — | $14.85 |
| 2025 | — | −$6.01 | $0.03 | −$5.14 | — | $19.53 |